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trial Fibrillation*
he Ancient Conundrum
efies Simple Solution
artin E. Goldman, MD, FACC,
ori B. Croft, MD, FACC
ew York, New York
“. . . Eli sat on his seat by the wayside watching;
for his heart trembled . . .” Samuel I, 4:13
trial fibrillation (AF), affecting 2% to 4% of adults aged 60
ears and older and more than 10% of patients older than 80
ears (1), is heralded with the onset of dyspnea, chest
iscomfort, palpitations, or simply fatigue, as the Biblical
udge, Eli, experienced (possibly the earliest description of
F). However, as many as one-third of patients may have
symptomatic or “silent” AF, which is more common in the
lderly (2).
OES SILENT AF
REDISPOSE ONE TO SILENT STROKE?
omputed tomographic imaging in 141 asymptomatic sub-
ects with non-valvular AF revealed that 36 (26%) had a
ypodense area consistent with a cerebral infarction (3).
ilent stroke has significant ramifications even though it is
y definition “asymptomatic.” Elderly people with silent
rain infarct on cerebral magnetic resonance imaging (MRI)
ave greater than double the risk of dementia and a steeper
ecline in global cognitive function (4).
See page 1807
The current study by Bernhardt et al. (5) in this issue of
he Journal reinforces the dangers of AF even with apparent
dequate anticoagulation and rate control. They followed
28 patients with nonvalvular AF and dense spontaneous
cho contrast (SEC) in the left atrial appendage (LAA)
ompared with 143 patients with faint SEC. During the
ubsequent 12 months, 2% had symptomatic cerebral em-
olism, 6% died as the result of their embolic event, and
5% had silent embolism. Those patients with a cerebro-
mbolism, clinical or silent, had a significantly lower LAA
mptying velocity and denser spontaneous echo contrast
ompared with patients without an event (similar to Stroke
revention Atrial Fibrillation [SPAF] III findings) (6).
Atrial fibrillation is a hypercoagulable state with elevated
brinogen, D-dimer, plasma C-reactive protein, soluble
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thed
merican College of Cardiology.
From the Mount Sinai Medical Center, New York, New York.-selectin, and von Willebrand factor. Stasis in the LAA
an lead to fibrinogen-promoted red blood cell aggregation,
orming dense SEC (7). The combination of stasis and
ypercoagulable state may promote thrombus formation.
hus, by confirming the presence of low contractile velocity
nd “dense SEC” in the LAA, transesophageal echo may be
ble to identify patients at highest risk for subsequent
linical and/or silent cerebrovascular events despite adequate
nticoagulation.
HY DIDN’T WARFARIN
REVENT THE CEREBROVASCULAR EVENTS?
he current guideline for warfarin anticoagulation in pa-
ients with sustained paroxysmal AF at high risk of stroke is
target international normalized ratio (INR) of 2.5, range
f 2 to 3.0 (8). In the current study, patients with nonval-
ular AF and dense spontaneous echo contrast had an
ncreased risk of cerebral embolism or death despite con-
inued oral anticoagulation, with a mean INR of 2.3  0.3
5). Confounding compulsive supervision, patients may dip
elow the magic number INR of 2.0. In a meta-analysis of
1 studies involving patients with nonvalvular AF on
arfarin, 26.0% of patients were below the therapeutic
arget INR of 2 to 3, with a 2.1% incidence of clinically
pparent cardioembolic events (9). Thus, warfarin may not
e absolutely effective in preventing large, clinical emboli
or emboli to clinically silent, compensated, or “nonelo-
uent” regions of the brain.
AN WE IMPROVE ON WARFARIN PROPHYLAXIS?
recent randomized, multicenter trial from Spain of 1,209
atients examined the use of anticoagulants (acenocou-
arol), antiplatelets (triflusal), or combination therapy in
ntermediate- and high-risk patients with AF (10). The
edian INRs in the intermediate- and high-risk groups
ere 1.93 and 2.17, respectively. The combined therapy of
nticoagulant and antiplatelet medication resulted in a lower
ncidence of vascular death, nonfatal stroke, and systemic
mbolism than either alone, with no difference in the
ncidence of severe bleeding. Despite the greater potential
isk of bleeding, the Seventh American Chest Physicians
onference on Antithrombotic and Thrombolytic Therapy
ecommended adding aspirin in doses up to 100 mg/day to
ral anticoagulation (target INR 2 to 3) in patients with AF
nd atherosclerosis to prevent ischemic coronary events (8).
hus, randomized trials with medications available in the
.S. are warranted to determine whether a combination of
nticoagulant and antithrombotic agents could prevent even
ilent events at an acceptable risk, particularly in the elderly.
S AF RATE CONTROL AN ACCEPTABLE GOAL?
wo recent large studies (Rate Control vs. Electical Car-
ioversion for Persistent Atrial Fibrillation [RACE] and
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Editorial Comment June 7, 2005:1813–4trial Fibrillation Follow-up Investigation of Rhythm
anagement [AFFIRM]) that compared rate control ver-
us rhythm control in AF concluded that rhythm control
ffered no survival advantage over rate control (11,12).
owever, a follow-up of the AFFIRM study according to
he actual treatment patients received, not by intention to
reat as reported in the initial article, demonstrated that the
resence of sinus rhythm was associated with a lower risk of
eath (13). Additionally, Hsu et al. (14) demonstrated that
atients with congestive heart failure in sinus rhythm after
F ablation had significant improvement in left ventricular
unction, exercise capacity, and quality of life at 12 months.
hus, an effective strategy for maintaining sinus rhythm
ith minimal adverse effects might improve function and
urvival in patients with AF and eliminate embolic compli-
ations.
AN SINUS RHYTHM BE MAINTAINED?
multivariate analysis of the AFFIRM study reported
hat of 2,033 patients who received 3,030 exposures to
ntiarrhythmic drugs, the risk of an adverse arrhythmic
vent was reasonably low (15). However, 50% of
atients on an antiarrhythmic regimen will remain in
inus rhythm at the end of one year, mandating continued
hronic anticoagulation.
Ablation of AF foci is one of the non-pharmacologic
herapies for eradicating AF. The surgical Maze procedure
as a 90% success rate of maintaining sinus rhythm (16).
lectrophysiologists have adapted the Corridor and Maze
rocedures with pulmonary vein isolation procedures with
imilar success rates. However, complications of catheter
blation include stroke, cardiac perforation, cardiac tampon-
de, atrial-ventricular heart block, and pulmonary vein
tenosis and thrombosis.
Both patient-activated and automatic atrial antitachy-
ardic pacing therapies have been used to painlessly treat
trial arrhythmias. The “pill-in-the-pocket” treatment of
aroxysmal AF was recently described using either flecain-
de or propafenone and was shown to restore sinus rhythm
n 94% of patients treated within 36  93 min (17).
owever, episodes of “silent AF” would not be self-treated,
xposing the subject to the risk of cardioembolism.
Thus, the current study emphasizes the dangers of AF
ven when the rate is well controlled and the patient is
eemingly adequately anticoagulated. With the aging of the
opulation, more patients will present with clinical or silent
trial AF. Strategies designed for AF rate control, even with
dmirable attempts at maintaining adequate INRs, may
xpose patients to risks of major embolic events and their
equelae and/or silent cerebral emboli, with subsequent
evelopment of cognitive impairment that otherwise is
ttributable to aging alone. Aggressive strategies providingetter pharmacologic antiembolic protection while main-
aining sinus rhythm with pharmacologic, percutaneous
blation, or implantable defibrillators appear preferable to
F rate control.
eprint requests and correspondence: Dr. Martin E. Goldman,
t. Sinai Medical Center, Cardiology, Box 1030, One Gustave
evy Place, New York, New York 10029. E-mail: martin.
oldman@mssm.edu.
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